Loomis Sayles & Co. L P lifted its position in shares of Doximity, Inc. (NASDAQ:DOCS - Free Report) by 2.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 2,334,597 shares of the company's stock after buying an additional 62,366 shares during the quarter. Loomis Sayles & Co. L P owned approximately 1.25% of Doximity worth $124,644,000 at the end of the most recent quarter.
A number of other institutional investors have also modified their holdings of DOCS. Global Retirement Partners LLC lifted its position in Doximity by 468.1% during the fourth quarter. Global Retirement Partners LLC now owns 534 shares of the company's stock worth $29,000 after buying an additional 440 shares during the period. UMB Bank n.a. lifted its holdings in shares of Doximity by 69.1% during the 4th quarter. UMB Bank n.a. now owns 575 shares of the company's stock worth $31,000 after acquiring an additional 235 shares during the period. Larson Financial Group LLC lifted its holdings in shares of Doximity by 49.4% during the 4th quarter. Larson Financial Group LLC now owns 756 shares of the company's stock worth $40,000 after acquiring an additional 250 shares during the period. Optimum Investment Advisors acquired a new stake in shares of Doximity in the fourth quarter worth approximately $43,000. Finally, Morse Asset Management Inc purchased a new stake in Doximity in the third quarter valued at approximately $46,000. Institutional investors and hedge funds own 87.19% of the company's stock.
Analysts Set New Price Targets
A number of brokerages have weighed in on DOCS. Stephens began coverage on shares of Doximity in a report on Friday, December 20th. They issued an "equal weight" rating and a $55.00 price target on the stock. Wells Fargo & Company reiterated an "equal weight" rating on shares of Doximity in a report on Friday, February 7th. Leerink Partners upgraded Doximity from a "market perform" rating to an "outperform" rating and upped their price target for the stock from $60.00 to $90.00 in a research note on Friday, February 7th. Mizuho lifted their price objective on Doximity from $55.00 to $65.00 and gave the company a "neutral" rating in a research note on Monday, February 10th. Finally, Bank of America increased their target price on shares of Doximity from $54.00 to $57.00 and gave the stock a "neutral" rating in a research report on Monday, January 6th. Eleven equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $64.22.
Check Out Our Latest Stock Analysis on Doximity
Insider Buying and Selling
In other news, Director Timothy S. Cabral sold 20,000 shares of the firm's stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $57.62, for a total value of $1,152,400.00. Following the transaction, the director now directly owns 6,360 shares in the company, valued at approximately $366,463.20. This trade represents a 75.87 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 37.40% of the stock is currently owned by company insiders.
Doximity Price Performance
NASDAQ:DOCS traded down $1.23 during mid-day trading on Monday, reaching $57.29. The stock had a trading volume of 805,865 shares, compared to its average volume of 1,942,608. The stock's 50 day simple moving average is $65.48 and its two-hundred day simple moving average is $54.55. Doximity, Inc. has a 1-year low of $22.96 and a 1-year high of $85.21. The company has a market capitalization of $10.69 billion, a price-to-earnings ratio of 57.28, a price-to-earnings-growth ratio of 4.10 and a beta of 1.34.
Doximity Company Profile
(
Free Report)
Doximity, Inc operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers.
Further Reading
Before you consider Doximity, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Doximity wasn't on the list.
While Doximity currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
